Will Biogen Drug Score Big At Alzheimer’s Conference?

By | March 11, 2015

Scalper1 News

A new research note from RBC Capital Markets offers a bullish take on Biogen Idec’s (BIIB) experimental drug for Alzheimer’s disease, predicting it will make a big splash at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases. The conference, scheduled for March 18-22 in Nice, France, attracts medical and scientific professionals from across the globe. Biogen is expected to show “best in class” data for its BIIB037 Scalper1 News

Scalper1 News